Leap Investments’s Nektar Therapeutics NKTR Stock Holding History

Leap Investments’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,500	Closed	-$486K	–	498
2019 Q4	$486K	Buy	+1,500	New	+$435K	0.23%	154

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Leap Investments's NKTR Position: Q1 2020 in Review

Leap Investments sold out of Nektar Therapeutics (NKTR) in Q1 2020, closing a stake of 1,500 shares — an estimated $486K sold.

Leap Investments first reported a position in NKTR in Q4 2019 and held it in 1 quarter. The position peaked at $486K in Q4 2019. 245 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

Leap Investments reported no remaining Nektar Therapeutics position as of Q1 2020 after selling out during the quarter.
Leap Investments sold 1,500 Nektar Therapeutics shares in Q1 2020, an estimated $486K.
Leap Investments first reported a position in Nektar Therapeutics in Q4 2019 and held it in 1 quarter.
Leap Investments's Nektar Therapeutics position peaked at $486K in Q4 2019.
245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.